Lab validation of immune cell therapy for MCPyV-positive Merkel cell carcinoma
Official title: Validation of in Vitro Method for Anti-MCPyV Immunotherapy on Patients With Merkel Cell Carcinoma of Skin
Run by Assistance Publique - Hôpitaux de Paris · NCT06780475 · Data updated 2026-11-12
The team will test a lab-based immune cell therapy on tumor or blood samples from adults with MCPyV-positive Merkel cell carcinoma to see how the cells respond.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 15 (estimated) |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Boulogne-Billancourt) |
| Status | Recruiting |
| Started | May 27, 2025 |
| Main results expected | May 2027 |
| Study ends | May 2027 |
| Registry record updated | November 19, 2025 |
| Trial ID | NCT06780475 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults (≥18) diagnosed with Merkel cell carcinoma of the skin, especially those known or suspected to be MCPyV-positive, who are receiving local or systemic care or active follow-up at the recruiting center and can give informed consent.
✕Probably not a fit
Patients who are pregnant or breastfeeding, under guardianship, enrolled in another interventional clinical trial, or whose tumors are MCPyV-negative should expect no direct clinical benefit from participation and may be ineligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The study collects tumor or blood samples from adults with Merkel cell carcinoma who are treated or followed at Ambroise Paré Hospital and applies an anti-MCPyV cell therapy in the laboratory. Researchers will expose patient-derived samples to the proposed cell therapy in vitro and measure tumor cell killing and immune activation. The primary aim is to validate the laboratory method and identify which patient samples show a response. This is an observational, bench-based validation and does not deliver the investigational therapy to patients.
Why it matters
Potential benefit: If successful, this work could help develop a targeted immune cell therapy for MCPyV-positive tumors and guide selection of patients for future clinical treatment.
How similar studies have gone: Laboratory and early preclinical MCPyV-targeted immune approaches have shown promising signals, but clinical benefit in patients has not been established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients \>= 18 years old; * Diagnosed with Merkel cell carcinoma of skin, ongoing for local treatment, systemic treatment, complementary treatment or an active follow-up; * Informed for the study and no-opposed for participation; * Affiliated with a social security scheme or in an equivalent situation. Exclusion Criteria: * Patients ongoing another interventional clinical trial; * Patients under guardianship or trusteeship; * Pregnancy or breastfeed; * Patients refusal.
Where it's running
-
Dermato-oncology Department, Ambroise Paré Hospital, APHP
Boulogne-Billancourt, France Recruiting
Study contacts
- Principal investigator: Astrid Blom, MD — Dermato-oncology Department, Ambroise Paré Hospital, APHP
- Study coordinator: Astrid Blom, MD
- Email: astrid.blom@aphp.fr
- Phone: +33 (01) 49 09 44 82
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
First-in-human test of KUP-101A in selected advanced skin cancers
This early study tests KUP-101A to see if it's safe and tolerable and to gather initial clues about its activity in patients with advanced skin cancers.
-
Treatment of advanced solid tumors with VET3-TGI immunotherapy
This study is testing a new cancer treatment called VET3-TGI to see if it can safely target and kill cancer cells in patients with advanced solid tumors, either by injecting it directly into the tumors or giving it through an IV.
-
Lifileucel (TIL) plus chemotherapy and IL-2 for advanced cutaneous squamous cell and Merkel cell carcinoma
This trial will try lifileucel (tumor-infiltrating lymphocytes) combined with lymphodepleting chemotherapy and interleukin-2 in adults with unresectable or metastatic cutaneous squamous cell carcinoma or Merkel cell carcinoma who have previously received immunotherapy.
-
In-home cancer treatment with remote specialist support for patients in the Florida Panhandle
This program will try giving standard cancer treatments at home to people living in the Florida Panhandle and nearby areas to see if they prefer it and have better treatment satisfaction.
-
Testing AZD6750 safety in adults with selected advanced or metastatic solid tumors
This trial tests whether AZD6750, a CD8-guided IL-2 medicine given alone or with other cancer drugs, is safe and how it behaves in adults with certain advanced or metastatic solid tumors.
-
Phase I testing of 225Ac-ETN029 for advanced DLL3-positive tumors
This trial will test 225Ac-ETN029, with 111In-ETN029 used for imaging, to see if the treatment is safe, tolerable, and shows early anti-tumor activity in adults with advanced DLL3-positive neuroendocrine cancers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.